0.542
-0.02 (-3.71%)
Previous Close | 0.563 |
Open | 0.545 |
Volume | 761,455 |
Avg. Volume (3M) | 1,748,679 |
Market Cap | 41,692,588 |
Price / Sales | 808.47 |
Price / Book | 36.17 |
52 Weeks Range | |
Earnings Date | 11 Nov 2024 - 15 Nov 2024 |
Operating Margin (TTM) | -51,661.19% |
Diluted EPS (TTM) | -0.780 |
Total Debt/Equity (MRQ) | 915.08% |
Current Ratio (MRQ) | 0.460 |
Operating Cash Flow (TTM) | -30.23 M |
Levered Free Cash Flow (TTM) | -18.18 M |
Return on Assets (TTM) | -92.94% |
Return on Equity (TTM) | -914.66% |
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Mixed | Mixed |
Biotechnology (Global) | Mixed | Mixed | |
Stock | Eyenovia, Inc. | Mixed | Mixed |
Stockmoo Score
Analyst Consensus | 2.5 |
Insider Activity | NA |
Price Volatility | 0.5 |
Technical Moving Averages | 2.5 |
Technical Oscillators | 0.5 |
Average | 1.50 |
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Small Value |
% Held by Insiders | 10.00% |
% Held by Institutions | 13.69% |
Ownership
Name | Date | Shares Held |
---|---|---|
Lasry Marc | 30 Jun 2024 | 547,807 |
52 Weeks Range | ||
Median | 12.00 (2,113.61%) | |
Total | 1 Buy |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
HC Wainwright & Co. | 13 Aug 2024 | 12.00 (2,113.61%) | Buy | 0.798 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |